Sun Pharma buys Organon for 11 75 billion boosting scale but integration debt could bite

The prize is global reach but the risk is integration

Sun Pharma’s $11.75 billion acquisition of Organon & Co is set to expand its global footprint, commercial reach, and product diversification, including women’s health and biosimilars. The move aims to strengthen long-term growth, but success will hinge on how smoothly management integrates Organon’s operations and controls the deal’s debt burden.